Macrophage Reversal of Anti-Lymphocyte Serum Induced Immunosuppression

  • J. C. Pisano
  • J. T. Patterson
  • N. R. Di Luzio
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 15)


The development of organ and tissue transplantation as a relatively common surgical procedure has necessitated the employment of immunosuppressive drug therapy in order to eliminate or delay the onset of immunologically-mediated tissue rejection mechanisms by the recipient (1). A wide variety of immunosuppressives, including antimetabolites, e.g., the purine analogs; alkylating agents, e.g., cyclophosphamide; and specific anticellular sera, e.g., antilymphocyte serum (ALS), have been employed. Unfortunately, a common side effect of nearly all immunosuppressive therapy is the development of post-transplant infections and tumor metastases (2–4). Indeed, Berenbaum (2) reported that up to 30% of renal transplantation failures have been associated with infection, while Starzl and Marchioro (3) have found 50% or more of hepatic transplantation failures to be associated with infections. Similarly, Wilson (4) has claimed that patients subjected to immunosuppressive therapy constitute a high risk group in terms of increased incidence of neoplasia.


Kupffer Cell Lipid Emulsion Liver Slice Normal Rabbit Serum Methyl Palmitate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schwartz, R. J., In Human Transplantation, Rappaport, F. T., and Dausset, J., Eds. Grune & Stratton, New York, 1968, p. 440.Google Scholar
  2. 2.
    Berenbaum, M. C., In Tissue and Organ Transplantation, Porter, K. A., Ed., Brit. Med. Assoc, London, 1968, p. 471.Google Scholar
  3. 3.
    Starzl, T. E. and T. L. Marchioro, In Human Transplantation, Rappaport, F. T. and Dausset, J. Ed., Grune and Stratton, New York, 1968, p. 215.Google Scholar
  4. 4.
    Wilson, D. B., Science, 169:1006, 1970.PubMedCrossRefGoogle Scholar
  5. 5.
    James, K., Clin. Chem. Acta. 22:101, 1968.CrossRefGoogle Scholar
  6. 6.
    Harris, S. and T. N. Harris, J. Immunol. 96:478, 1966.PubMedGoogle Scholar
  7. 7.
    Kerby, G. P. and S. P. Martin. J. Exptl. Med. 93:189, 1951.CrossRefGoogle Scholar
  8. 8.
    Jooste, S. V. Lymphology. 3:72, 1970.Google Scholar
  9. 9.
    Di Luzio, N. R. and S. J. Riggi, J. Reticuloendothelial Soc. 1:126, 1964.Google Scholar
  10. 10.
    Saba, T. M., J. P. Filkins, and N. R. Di Luzio, J. Reticuloendothelial Soc. 3:398, 1966.Google Scholar
  11. 11.
    Pisano, J. C., J. T. Patterson, and N. R. Di Luzio, Science 162:565, 1968.PubMedCrossRefGoogle Scholar
  12. 12.
    Mosier, D. E., Science 158:1573, 1967.PubMedCrossRefGoogle Scholar
  13. 13.
    Pisano, J. C., J. P. Filkins, and N. R. Di Luzio. Proc. Soc. Exptl. Biol. Med. 128:917, 1968.Google Scholar
  14. 14.
    Wooles, W. R. and N. R. Di Luzio, Science 142:1078, 1963.PubMedCrossRefGoogle Scholar
  15. 15.
    Saba, T. M. and N. R. Di Luzio, Am. J. Physiol. 216:910, 1969.PubMedGoogle Scholar
  16. 16.
    Feldman, M. and R. Gallily, In Ontogeny of Immunity, Smith, R. T., R. A. Good and P. A. Miescher, Eds., Univ. of Fla. Press, 1967, p. 39.Google Scholar

Copyright information

© Plenum Press, New York 1971

Authors and Affiliations

  • J. C. Pisano
    • 1
  • J. T. Patterson
    • 1
  • N. R. Di Luzio
    • 1
  1. 1.Department of PhysiologyTulane University School of MedicineNew OrleansUSA

Personalised recommendations